CNBC Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the obesity drug space.
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the obesity drug space.